These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 12201674

  • 1. Synergistic enhancement of the antitumor effect of taxol by the bioreductive compound NLCQ-1, in vivo: comparison with tirapazamine.
    Papadopoulou MV, Ji M, Bloomer WD.
    Oncol Res; 2002; 13(1):47-54. PubMed ID: 12201674
    [Abstract] [Full Text] [Related]

  • 2. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine.
    Papadopoulou MV, Ji M, Rao MK, Bloomer WD.
    Oncol Res; 2001; 12(8):325-33. PubMed ID: 11589303
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic advantage from combining 5-fluorouracil with the hypoxia-selective cytotoxin NLCQ-1 in vivo; comparison with tirapazamine.
    Papadopoulou MV, Ji M, Ji X, Bloomer WD.
    Cancer Chemother Pharmacol; 2002 Oct; 50(4):291-8. PubMed ID: 12357303
    [Abstract] [Full Text] [Related]

  • 4. Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice.
    Papadopoulou MV, Ji M, Bloomer WD.
    Cancer Chemother Pharmacol; 2001 Aug; 48(2):160-8. PubMed ID: 11561782
    [Abstract] [Full Text] [Related]

  • 5. Potentiation of alkylating agents by NLCQ-1 or TPZ in vitro and in vivo.
    Papadopoulou MV, Ji X, Bloomer WD.
    J Exp Ther Oncol; 2006 Aug; 5(4):261-72. PubMed ID: 17024967
    [Abstract] [Full Text] [Related]

  • 6. Enhancement of the antitumor effect of cyclophosphamide with the hypoxia-selective cytotoxin NLCQ-1 against murine tumors and human xenografts.
    Papadopoulou MV, Ji M, Bloomer WD, Hollingshead MG.
    J Exp Ther Oncol; 2002 Aug; 2(5):298-305. PubMed ID: 12416033
    [Abstract] [Full Text] [Related]

  • 7. Synergistic interaction between cyclophosphamide or paclitaxel and the bioreductive compound NLCPQ-1, in vivo.
    Papadopoulou MV, Ji M, Bloomer WD.
    Oncol Res; 2003 Aug; 13(12):561-6. PubMed ID: 12899246
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice.
    Papadopoulou MV, Ji M, Ji X, Bloomer WD, Hollingshead MG.
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):501-8. PubMed ID: 12451478
    [Abstract] [Full Text] [Related]

  • 9. Hypoxia-dependent retinal toxicity of NLCQ-1 (NSC 709257) in BALB/c mice. Comparison with tirapazamine.
    Papadopoulou MV, Ji M, Bloomer WD.
    Basic Clin Pharmacol Toxicol; 2011 Jun; 108(6):396-9. PubMed ID: 21205223
    [Abstract] [Full Text] [Related]

  • 10. NLCQ-1, a novel hypoxic cytotoxin: potentiation of melphalan, cisDDP and cyclophosphamide in vivo.
    Papadopoulou MV, Ji M, Bloomer WD.
    Int J Radiat Oncol Biol Phys; 1998 Nov 01; 42(4):775-9. PubMed ID: 9845094
    [Abstract] [Full Text] [Related]

  • 11. DNA repair mechanisms are involved in the hypoxia-dependent toxicity of NLCQ-1 (NSC 709257) and its synergistic interaction with alkylating agents.
    Papadopoulou MV, Bloomer WD.
    In Vivo; 2007 Nov 01; 21(2):175-80. PubMed ID: 17436565
    [Abstract] [Full Text] [Related]

  • 12. Mechanisms involved in the potentiation of paclitaxel or 5-fU by the hypoxic cytotoxin NLCQ-1 (NSC 709257) in vitro.
    Papadopoulou MV, Ji X, Bloomer WD.
    Anticancer Res; 2005 Nov 01; 25(3B):2161-70. PubMed ID: 16158959
    [Abstract] [Full Text] [Related]

  • 13. NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug.
    Papadopoulou MV, Bloomer WD.
    Clin Cancer Res; 2003 Nov 15; 9(15):5714-20. PubMed ID: 14654556
    [Abstract] [Full Text] [Related]

  • 14. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxin.
    Papadopoulou MV, Ji M, Rao MK, Bloomer WD.
    Oncol Res; 2000 Nov 15; 12(4):185-92. PubMed ID: 11341468
    [Abstract] [Full Text] [Related]

  • 15. Investigational new drug-directed, 5-day repeat dose toxicity study of 4-[3-(2-nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1, NSC 709257) administered with or without Taxol in Sprague-Dawley rats.
    Papadopoulou MV, Bloomer WD, Torti VR, Page JG.
    Basic Clin Pharmacol Toxicol; 2010 Jun 15; 106(6):497-504. PubMed ID: 20074267
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Tirapazamine: a new drug producing tumor specific enhancement of platinum-based chemotherapy in non-small-cell lung cancer.
    Wouters BG, Wang LH, Brown JM.
    Ann Oncol; 1999 Jun 15; 10 Suppl 5():S29-33. PubMed ID: 10582136
    [Abstract] [Full Text] [Related]

  • 18. Potentiation of cisplatin activity by the bioreductive agent tirapazamine.
    Siemann DW, Hinchman CA.
    Radiother Oncol; 1998 May 15; 47(2):215-20. PubMed ID: 9683372
    [Abstract] [Full Text] [Related]

  • 19. Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine.
    Friery OP, Gallagher R, Murray MM, Hughes CM, Galligan ES, McIntyre IA, Patterson LH, Hirst DG, McKeown SR.
    Br J Cancer; 2000 Apr 15; 82(8):1469-73. PubMed ID: 10780528
    [Abstract] [Full Text] [Related]

  • 20. Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia.
    Siim BG, Menke DR, Dorie MJ, Brown JM.
    Cancer Res; 1997 Jul 15; 57(14):2922-8. PubMed ID: 9230202
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.